However, it is our present position that the preferred therapy for chronic recalcitrant urticaria not responding to high-dose antihistamines and/or standard immunosuppressive drugs should be omalizumab, and that TNF-alpha inhibitors should be recommended as a second-line therapeutic option. The gene discussed is TNF; the disease is urticaria.